BRCA1 and cancer: An example may be the use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis), drugs with already proven effectiveness in humans, for treatment of patients with DNA damage repair-deficient cancers, mainly with Breast Cancer Associated 1 and 2 (BRCA1 and BRCA2) mutations [1].